BioVersys, TASK and GSK receive 2.7 million Euro from EDCTP for Phase 2a Clinical Trial

BVL-GSK098 AND ETHIONAMIDE COMBINATION IS BEING DEVELOPED FOR THE TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS INFECTIONS